乳腺癌ER、PR、Ki67表达与临床病理的关系

Relationship Between Expression of ER, PR and Ki67 and Clinicopathology in Breast Cancer

目的:分析乳腺癌雌激素受体(ER)、孕激素受体(PR)、Ki67表达与临床病理的关系。方法:选取2013年1月至2018年12月到建宁县总医院就诊的乳腺癌患者80例,使用免疫组化方法检测患者ER、PR、Ki67水平。进行4个周期的化疗后,根据WHO实体瘤疗效标准,将患者分为缓解组(n=45)和未缓解组(n=35),比较两组的ER、PR、Ki67表达率、远处转移率、无瘤生存率、总生存率,分析其与乳腺癌恶性程度的关系。结果:缓解组的ER、PR、Ki67表达率和远处转移率明显低于未缓解组,无瘤生存率、总生存率明显高于未缓解组,差异具有统计学意义(P<0.05)。结论:ER、PR、Ki67阳性表达率越高,乳腺癌的恶性程度总体越强。

Objective To analyze the relationship between the expression of ER,PR and Ki67 and clinicopathology in breast cancer.Methods Eighty breast cancer patients who were admitted to Jianning general hospital from January to February 2018 in 2013 were enrolled.The levels of ER,PR and Ki67 were detected by immunohistochemistry.After 4 cycles of chemotherapy,patients were divided into remission group(n=45)and non-remission group(n=35)according to WHO solid tumor efficacy criteria.The expression rates of ER,PR and Ki67 in the two groups were compared.Metastasis rate,tumor-free survival rate,and overall survival rate were analyzed for their relationship with the degree of malignancy of breast cancer.Results The expression rates of ER,PR,Ki67 and distant metastasis in the remission group were significantly lower than those in the non-remission group.The tumorfree survival rate and overall survival rate were significantly higher than those in the non-remission group(P<0.05).Conclusion The higher the positive expression rate of ER,PR and Ki67,the stronger the malignant degree of breast cancer,and it can be used clinically.